Clinical Report: Sustained-Release Steroid vs Anti-VEGF Therapy
Overview
The NEW DAY trial compared a sustained-release fluocinolone acetonide implant with aflibercept in patients with retinal vascular disease. The fluocinolone implant demonstrated a reduction in the frequency of intraocular pressure (IOP) concerns and maintained optical coherence tomography (OCT) thickness stability compared to aflibercept.
Background
Retinal vascular diseases, such as diabetic macular edema (DME), pose significant challenges in clinical management. The advent of sustained-release therapies offers potential advantages in reducing treatment burden and improving patient outcomes. Understanding the comparative efficacy and safety of these therapies is crucial for optimizing treatment strategies.
Data Highlights
The NEW DAY trial involved 306 treatment-naïve patients with center-involved diabetic macular edema (CI-DME) over an 18-month follow-up period.
Key Findings
- The fluocinolone acetonide implant required fewer supplemental injections compared to aflibercept, although this did not reach statistical significance.
- Significant stability in OCT thickness was observed with fluocinolone, while OCT measurements fluctuated with monthly anti-VEGF injections.
- Intraocular pressure (IOP) over 25 mmHg was monitored, with a positive predictive value of 94% for IOP concerns by the end of the trial.
- Only 1.9% of patients required incisional glaucoma surgery during the study.
- Two out of three patients with optic nerve edema returned to baseline measurements after treatment with fluocinolone.
- The positive predictive value for an 8 µm difference in RNFL measurements was 92%.
Clinical Implications
Regular follow-up every three months is recommended to monitor IOP and retinal nerve fiber layer changes.
Conclusion
The NEW DAY trial presents findings on the use of sustained-release steroid therapy in retinal vascular diseases.
Related Resources & Content
- American Diabetes Association, Diabetes Care, 2026 -- Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes
- Ophthalmology Management, 2014 -- Four key advances in the battle against retinal disease
- Ophthalmology Management, 2022 -- SUSTAINED ANTI-VEGF DELIVERY
- Retinal Physician, 2018 -- Durable Treatment for Macular Degeneration
- Retinal Physician — Improving Durability of Drugs in Wet AMD
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
- https://m1.healio.com/~/media/images/education-lab/activity-images/2025/ophthalmology/h492/h491_dme_osnny_slides_for_download.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
